NCT07239440

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 288 (estimated)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, double-blind, active-controlled, randomized, parallel clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing BT-1 and BT-2 combination therapy in patients with type 2 diabetes who have inadequate glycemic control

Conditions

• Diabete Mellitus

Interventions

Type	Name	Description
DRUG	DA-2811	DA-2811 + DA-2811-R2, orally, once daily
DRUG	DA-2811-C	DA-2811-C + DA-2811-R1, orally, once daily

Timeline

• Start date: 2025-11-01
• Primary completion: 2026-12-01
• Completion: 2027-06-01
• First posted: 2025-11-20
• Last updated: 2025-11-20

Locations

1 site across 1 country: South Korea